A one-month supply of each covered insulin product will still cost no more than $35 in 2027, the same figure that has held since the cap took effect on January 1, 2023. That number survives a year in which the Centers for Medicare & Medicaid Services finalized a 2027 Part D benefit that raises the standard deductible to $700 and lifts the annual out-of-pocket ceiling to $2,400. The insulin figure does not move because it was never subject to the formula that moves those two numbers; it is a fixed dollar line Congress wrote into the Social Security Act, not one CMS recalculates each year from drug-spending trends.
A Statutory Line, Not an Annual CMS Calculation
The $35 cap originates in Section 11406 of the Inflation Reduction Act, which added a new cost-sharing limit to the Act for any insulin product included on a Part D sponsor’s formulary. The provision covers new insulin products added mid-year and extends to insulin delivered through a traditional pump covered under Medicare Part B’s durable medical equipment benefit, capped the same way since July 1, 2023. Because the dollar figure is written directly into statute rather than delegated to CMS rulemaking, the 2027 plan year did not require the agency to publish a new insulin threshold; it simply carried the existing $35 ceiling forward into the finalized Contract Year 2027 rule.
That structure sets insulin apart from most other Part D cost-sharing figures, which are recalculated annually using a statutory methodology tied to projected per-enrollee drug spending. The deductible, the initial coverage phase, and the out-of-pocket threshold all move with that formula most years, sometimes sharply. Insulin cost-sharing does not participate in that recalculation at all, which is why Medicare’s own coverage page still states no more than $35 for a one-month supply of each covered insulin product, with no deductible applied first.
Free retirement updates: One number can cost or save hundreds a month in retirement. The free Retirement Shield newsletter surfaces the ones worth knowing. Sign up free.
The Rest of Part D Keeps Getting More Expensive Around It
CMS’s finalized Contract Year 2027 Medicare Advantage and Part D rule, published April 6, 2026, raises the standard initial deductible from $615 in 2026 to $700 in 2027 and lifts the annual out-of-pocket spending threshold from $2,100 to $2,400, a jump of roughly 14 percent on each figure in a single year. Both figures have climbed every year since the Inflation Reduction Act restructured Part D into its current three-phase design, and both are set to keep climbing under the statutory adjustment method CMS applies each fall.
For a beneficiary filling an expensive brand-name drug that is not insulin, that increase is real money: reaching the deductible-free catastrophic phase now requires roughly $300 more in retail drug spending than it did entering 2026. The same final rule also codifies the Manufacturer Discount Program that helps finance the redesigned benefit, requiring manufacturers to cover 10 percent of costs in the initial phase and 20 percent in the catastrophic phase, with civil penalties for manufacturers that fall short. None of that financing structure touches the insulin carve-out, which sits outside the phase-by-phase cost-sharing math entirely.
The contrast is the practical story for 2027: a household managing several chronic conditions could see its non-insulin drug costs shift meaningfully with the new deductible and threshold, while its insulin costs stay exactly where they were the year the cap began. The same plan document that raises one number by hundreds of dollars leaves the other untouched, because only one of the two is treated as adjustable.
How the Cap Applies at the Pharmacy Counter
The $35 ceiling is calculated per insulin product, not per household or per prescription overall. A beneficiary using two distinct insulin products, for example a long-acting basal insulin and a fast-acting mealtime insulin, can be charged up to $35 for each, for a combined cost of up to $70 in a given month even though every dollar of that spending falls under the same statutory protection. A three-month supply of a single product is capped at $35 for each month’s supply within it, meaning the ceiling for that quantity works out to no more than $105 rather than a single flat $35 for the whole three-month fill.
The protection also does not distinguish among coverage phases or subsidy levels. It applies whether a beneficiary has met the annual deductible or not, since insulin is explicitly excluded from having to satisfy that deductible first, and it applies to enrollees receiving partial Extra Help just as it applies to those paying full retail cost-sharing. Beneficiaries with full Extra Help already pay less than $35 in most cases and continue to do so; the cap functions as a backstop for everyone else, unaffected by which phase of the benefit a person happens to be in on any given fill date.
What makes the 2027 plan year notable is not a new insulin policy but the widening gap between a number that moves and a number that does not. CMS’s own rulemaking record shows no proposal in the CY2027 cycle to alter the insulin cost-sharing limit, even as the agency simultaneously reset the deductible and out-of-pocket threshold upward for the fifth consecutive year under the IRA’s redesign. That asymmetry is a function of where each figure lives in the law: one is indexed to spending trends the agency recalculates on a schedule, the other is a flat number that only a future act of Congress could change.
For beneficiaries budgeting ahead of the 2027 plan year, the practical takeaway sits in that distinction. Rising deductibles and thresholds will show up in plan comparisons and premium notices well before January, but the insulin line on those same documents will not need updating, because it was never on the list of figures Medicare recalculates in the first place.
This article was researched and drafted with the assistance of artificial intelligence.
More Financial Reading
